Advertisement

Immunodeficiency and Multiple Primary Malignancies

  • Michele Santangelo
  • Sergio Spiezia
  • Marco Clemente
  • Andrea Renda
  • Arturo Genovese
  • Giuseppe Spadaro
  • Concetta D’Orio
  • Gianni Marone
  • Stefano Federico
  • Massimo Sabbatini
  • Eliana Rotaia
  • Pierluca Piselli
  • Claudia Cimaglia
  • Diego Serraino
Part of the Updates in Surgery book series (UPDATESSURG)

Abstract

The relationship between cancer onset and the immune response became a subject of great interest in the early 1900s, and led Ehrlich [1] to establish what came to be known as the theory of immunological surveillance. This theory is based on three principles: (1) cancer cells are antigenic, (2) these cells can be destroyed by the immune response of the organism (by a mechanism similar to that observed in transplanted tissue or organ rejection), and (3) immune depression is related to a higher incidence of neoplastic disease [2]. The theory is based on the concept that the immune system is able to recognize cancer cells as non-self and consequently to destroy them. Furthermore, this response involves both branches of the immune system. However, this defensive system is not as perfect as it may seem at first sight, because more often than not a certain number of cancer cells do avoid surveillance and subsequent destruction by immune-competent cells and thus continue to proliferate, until they give rise to the various forms of malignancies. The mechanisms by which cancer cells elude immunological surveillance may be explained by some intrinsic characteristics of these cells and/or the patient’s condition, including an immune deficiency.

Keywords

Human Immunodeficiency Virus Neoplastic Disease Primary Central Nervous System Lymphoma Human Immunodeficiency Virus Patient Rubella Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Piro A, Tagarelli A, Tagarelli G et al (2008) Paul Ehrlich. The nobel prize in phisiology or medicine 1908. Int Rev Immunol 27(1):1–17PubMedCrossRefGoogle Scholar
  2. 2.
    Totaro G, Ciardiello F, Bianco R (2003) Richiami di biologia dei tumori. In: Manuale di Oncologia Clinica. Mc Growe-Hill, MilanGoogle Scholar
  3. 3.
    Harrison A, Braunwald KD, Fauci E et al (2004) Harrison’s principles of internal medicine. Mc Grow-Hill, Milano ItaliaGoogle Scholar
  4. 4.
    Chinen J, Anmuth D, Franklin AR, Shearer WT (2007) Long-term follow-up of patients with primary immunodeficiencies. J Allergy Clin Immunol 120:795–797PubMedCrossRefGoogle Scholar
  5. 5.
    Ballow M (2002) Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol 109:581–591PubMedCrossRefGoogle Scholar
  6. 6.
    Meyn MS (1999) Ataxia-teleangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 55:289–304PubMedCrossRefGoogle Scholar
  7. 7.
    Cunningham-Rundles C, Bodian C (1999) Common Variable Immunodeficiency. Clinical and immunological features of 248 patients. Clin Immunol 92:34–48PubMedCrossRefGoogle Scholar
  8. 8.
    Mellemkjaer GP, Hammarstrom L, Andersen V et al (2002) Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 130:495–500PubMedCrossRefGoogle Scholar
  9. 9.
    World Health Organization, International Agency for Research on Cancer (1997) Epstein-Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. ARC, LyonGoogle Scholar
  10. 10.
    Wheat WH, Cool CC, Morimoto Y et al (2005) Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common 999333variable immunodeficiency. J Exper Med 202(4):479–484CrossRefGoogle Scholar
  11. 11.
    Bogstedt AK, Nava S, Wadstrom T, Hammarstrom L (1996) Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Clin Exp Immunol 105:202–204PubMedCrossRefGoogle Scholar
  12. 12.
    Zullo A, Romiti A, Rinaldi V et al (1999) Gastric pathology in patients with common variable immunodeficiency. Gut 45(1):77–81PubMedGoogle Scholar
  13. 13.
    Brosens LA, Tytgat KM, Morsink FH et al (2008) Multiple colorectal neoplasm in X-linked agammaglobulinemia. Clin Gastroenterol Hepatol 6(1): 115–119PubMedCrossRefGoogle Scholar
  14. 14.
    Berthoux F, Abramowicz D, Bradley B et al (2002) Best practice guidelines for renal transplantation (part 2). Nephrol Dial Transplant 17(suppl 4): 1–67Google Scholar
  15. 15.
    Sheil AG (2002) Organ transplantation and malignancy: inevitable linkage. Transplant Proc 34:2436–2437PubMedCrossRefGoogle Scholar
  16. 16.
    Gutierrez-Dalmau A, Campistol JM (2007) Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 67(8): 1167–1198PubMedCrossRefGoogle Scholar
  17. 17.
    Dantal J, Pohanka E (2007) Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 22(Suppl 1):i4–i10PubMedCrossRefGoogle Scholar
  18. 18.
    Jensen MK, Soborg M (1966) Chromosome aberrations in human cells following treatment with imuran. Preliminary report. Acta Med Scand 179(2):249–250PubMedGoogle Scholar
  19. 19.
    O’Donovan P, Perrett CM, Zhang X et al (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309(5742):1871–1874PubMedCrossRefGoogle Scholar
  20. 20.
    Hojo M, Morimoto T, Maluccio M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397(6719):471–472CrossRefGoogle Scholar
  21. 21.
    Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2): 128–135PubMedCrossRefGoogle Scholar
  22. 22.
    Robson R, Cecka JM, Opelz G et al (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5(12):2954–2960PubMedCrossRefGoogle Scholar
  23. 23.
    Rheingold SR, Neugut AI, Meadows AT (2000) Secondary cancer: incidence, risk factors and management. In: Holland JF, Frey E (eds) Cancer medicine. Decker, HamiltonGoogle Scholar
  24. 24.
    Penn I (1997) Overview of the problem of cancer in organ transplant recipients. Ann Transplant 2(4):5–6PubMedGoogle Scholar
  25. 25.
    Kauffman HM, Wida SC, Maureen A et al (2005) Transplant recipient with a history of a malignancy: risk of recurrent and de novo cancers. Transpl Rev 19:55–64CrossRefGoogle Scholar
  26. 26.
    Ponticelli C (2007) Medical complications of kidney transplantation. Informa Healtcare, LondonGoogle Scholar
  27. 27.
    Taioli E, Piselli P, Arbustini E et al (2006) Incidence of second primary cancer in transplanted patients. Transplantation 81(7):982–985PubMedCrossRefGoogle Scholar
  28. 28.
    Gandhi MJ, Strong DM (2007) Donor derived malignancy following transplantation: a review. Cell Tissue Bank 8(4):267–286PubMedCrossRefGoogle Scholar
  29. 29.
    Serraino D, Piselli P, Busnach G et al (2007) Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 43(14):2117–2123PubMedCrossRefGoogle Scholar
  30. 30.
    Neugut AI, Meadows AT, Robinson E (1999) Multiple primary cancer. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  31. 31.
    Hessol NA, Pipkin S, Schwarcz S et al (2007) The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 165(10): 1143–1153PubMedCrossRefGoogle Scholar
  32. 32.
    Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA (2007) AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99:962–972PubMedCrossRefGoogle Scholar
  33. 33.
    Akanmu AS (2006) AIDS-associated malignancies. Afr J Med Med Sci 35:57–70PubMedGoogle Scholar
  34. 34.
    Clifford GM, Polesel J, Rickenbach M et al (2005) Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking and highly active antiretroviral therapy. J Natl Cancer Inst 97:425–432PubMedGoogle Scholar
  35. 35.
    Frisc M, Biggar RJ, Engels EA, Goedert JJ (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA 285:1736–1745CrossRefGoogle Scholar
  36. 36.
    Grulich AE, Li Y, McDonald A (2002) Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 16:1155–1161PubMedCrossRefGoogle Scholar
  37. 37.
    Allardice GM, Hole DJ, Brewster DH et al (2003) Incidence of malignant neoplasm among HIV-infected persons in Scotland. Br J Cancer 89:505–507PubMedCrossRefGoogle Scholar
  38. 38.
    Dalmaso L, Franceschi S, Polesel J et al (2003) Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 89:94–100CrossRefGoogle Scholar
  39. 39.
    International collaboration on HIV and Cancer (2000) Highly active antirectroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92:1823–1830CrossRefGoogle Scholar
  40. 40.
    Arora A, Chiao E, Tyring SK (2007) AIDS malignancies. Cancer Treat Res 133:21–67PubMedCrossRefGoogle Scholar
  41. 41.
    Grulich AE, Leeuwen M, Falster M, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67PubMedCrossRefGoogle Scholar
  42. 42.
    Grulich AE, Wan X, Law MG et al (1999) Risk of cancer in people with AIDS. AIDS 13:839–843PubMedCrossRefGoogle Scholar
  43. 43.
    Antinori A, Larocca LM, Fassone L et al (1999) HHV-8/KSHV is not associated with AIDS-related primary central nervous system lymphoma. Brain Pathol 9(2): 199–208PubMedCrossRefGoogle Scholar
  44. 44.
    Manfredi R, Calza L, Chiodo F (2003) Multiple AIDS-related malignancies just in the era of potent antiretroviral therapy. A rare but intriguing finding. Infez Med 11(3): 153–156PubMedGoogle Scholar
  45. 45.
    Aviram G, Fishman JE, Schwartz DS (2001) Metachronous primary carcinomas of the lung in an HIV-infected patient. AIDS Patient Care STDS 15(6):297–300PubMedCrossRefGoogle Scholar
  46. 46.
    Mussi MG, Correa AR, Moraes DR et al (1996) Astrocytoma and squamous cell lung carcinoma association in AIDS patients. Int Conf AIDS 11:448Google Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Michele Santangelo
    • 1
  • Sergio Spiezia
    • 2
  • Marco Clemente
    • 1
  • Andrea Renda
    • 1
  • Arturo Genovese
    • 3
  • Giuseppe Spadaro
    • 3
  • Concetta D’Orio
    • 3
  • Gianni Marone
    • 3
  • Stefano Federico
    • 3
  • Massimo Sabbatini
    • 3
  • Eliana Rotaia
    • 3
  • Pierluca Piselli
    • 4
  • Claudia Cimaglia
    • 4
  • Diego Serraino
    • 5
  1. 1.Surgical, Anesthesiology-rianimative and Emergency Sciences DepartmentFederico II UniversityNaplesItaly
  2. 2.Unit of Screening and Follow-up for Hereditary and Familial Cancer, Department of Molecular and Clinical Endocrinology and OncologyFederico II UniversityNaplesItaly
  3. 3.Department of Clinical Medicine, Cardiovascular ed Immunologic SciencesFederico II UniversityNaplesItaly
  4. 4.Department of EpidemiologyINMI L. Spallanzani IRCCSRomeItaly
  5. 5.SOC Epidemiology & BiostatisticsCRO - IRCCSAviano (PN)Italy

Personalised recommendations